NETRIS Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137
NETRIS Pharma led consortium awarded €1.2 million Eurostar grant to explore netrin-1 targeted therapeutics
NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer
Δ40p53 isoform up-regulates netrin-1/UNC5B expression and potentiates netrin-1 pro-oncogenic activity
Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma Progression
As the world pioneer and leader biotech company targeting ligands of Dependence Receptors, NETRIS Pharma has built and is periodically reinforcing a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach and activity.
NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate partners.